Search results for "Ejection fraction"

showing 10 items of 378 documents

Genistein supplementation and cardiac function in postmenopausal women with metabolic syndrome: Results from a pilot strain-echo study

2017

Genistein, a soy-derived isoflavone, may improve cardiovascular risk profile in postmenopausal women with metabolic syndrome (MetS), but few literature data on its cardiac effects in humans are available. The aim of this sub-study of a randomized double-blind case-control study was to analyze the effect on cardiac function of one-year genistein dietary supplementation in 22 post-menopausal patients with MetS. Participants received 54 mg/day of genistein (n = 11) or placebo (n = 11) in combination with a Mediterranean-style diet and regular exercise. Left ventricular (LV) systolic function was assessed as the primary endpoint, according to conventional and strain-echocardiography measurement…

Cardiac function curvemedicine.medical_specialtycardiac function; echocardiography; genistein; menopause; metabolic syndromegenistein; metabolic syndrome; menopause; cardiac function; echocardiographyGenisteinlcsh:TX341-641030204 cardiovascular system & hematologyPlaceboArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineEnd-systolic volumeBody surface areaNutrition and DieteticsEjection fractionbusiness.industryCardiac functionHeartMiddle Agedmedicine.diseaseGenisteinMetabolic syndromePostmenopauseEndocrinologychemistryEchocardiographyDietary SupplementsCardiologyCardiac function; Echocardiography; Genistein; Menopause; Metabolic syndrome; Food ScienceFemaleMetabolic syndromeMenopausebusinesslcsh:Nutrition. Foods and food supplyFood Science
researchProduct

Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive r…

2011

Background— Diastolic dysfunction associated with high blood pressure (BP) leads to cardiac remodeling and fibrosis and progression to congestive heart failure. B-type natriuretic peptide (BNP) has BP-lowering, antifibrotic, and antihypertrophic properties, which makes BNP an attractive agent for attenuating the adverse cardiac remodeling associated with hypertension. In the current study, we tested the effects of sustained cardiac proBNP gene delivery on BP, cardiac function, and remodeling in spontaneously hypertensive rats (SHR). Methods and Results— We used the myocardium-tropic adeno-associated virus serotype 9 (AAV9) vector to achieve continuously enhanced cardiac rat proBNP expressi…

Cardiac function curvemedicine.medical_specialtymedicine.drug_classBNP; Natyriuretic peptides; hypertensive heart diseaseDiastolePhysiology (medical)Internal medicinemedicineNatriuretic peptideNatyriuretic peptidescardiovascular diseasesVentricular remodelingEjection fractionbusiness.industryheart failure natriuretic peptide hypertension.medicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareHypertensive heart diseaseBlood pressureEndocrinologyHeart failurecardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesshypertensive heart diseasehormones hormone substitutes and hormone antagonistsBNP
researchProduct

Ultrasonography in Heart Failure: A Story that Matters

2019

Abstract Heart failure (HF) is a clinical syndrome caused by structural and/or functional cardiac abnormalities, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress. It is the leading cause of hospitalization in Internal Medicine departments. This article aims at reviewing evidence of the importance of ultrasound in HF both for hospitalized patients and in the follow-up. Ultrasound may be used as a recovery monitoring instrument at the bedside and also as a global cardiovascular assessment tool for these patients. HF represents an exciting opportunity to create an integrative ultrasound approach in Internal Medicine and/or Geriatric departme…

Cardiac outputmedicine.medical_specialtySettore MED/09 - Medicina InternaHeart Ventriclesheart failure ultrasonography.heart failureIntracardiac pressure030204 cardiovascular system & hematologyCarotid Intima-Media ThicknessVentricular Function Leftultrasonography.03 medical and health sciences0302 clinical medicinemedicine.arteryInternal medicineHumansMedicine030212 general & internal medicineVeinUltrasonographyEjection fractionbusiness.industryUltrasoundAbdominal aortaReproducibility of ResultsStroke VolumeGeneral Medicinemedicine.diseasemedicine.anatomical_structureIntima-media thicknessEchocardiographyHeart failurecardiovascular systemCardiologyUltrasonographyHeart Failure “ABCDE” score LungCardiology and Cardiovascular Medicinebusiness
researchProduct

Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone t…

2007

Background and aims Cardiomyocyte apoptosis (CA) is a common feature of end-stage heart failure. We examined whether CA is associated with cardiac dysfunction and remodelling in heart failure due to dilated cardiomyopathy and studied the effect of human growth hormone (hGH) on CA. Methods and results We studied 38 patients, included in a phase III multi-center, randomised, double-blind and placebo-controlled trial of biosynthetic hGH treatment in dilated cardiomyopathy, at baseline and after 14 weeks treatment. Twenty-six patients received hGH and 12 received placebo. CA was quantified in endomyocardial biopsies using the TUNEL assay. CA correlated with left ventricular size (r=0.43, p=0.00…

Cardiomyopathy DilatedMalemedicine.medical_specialtyHeart VentriclesApoptosisPlaceboVentricular Dysfunction LeftInterquartile rangeSomatomedinsInternal medicinemedicineHumansMyocytes CardiacTUNEL assayEjection fractionbusiness.industryHuman Growth HormoneDilated cardiomyopathyStroke VolumeMiddle Agedmedicine.diseaseFas receptorImmunohistochemistryGrowth hormone treatmentEndocrinologyHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuropean journal of heart failure
researchProduct

Differential contribution of dead space ventilation and low arterial pCO2 to exercise hyperpnea in patients with chronic heart failure secondary to i…

2003

In chronic heart failure (CHF), the abnormally large ventilatory response to exercise (VE/VCO(2) slope) has 2 conceptual elements: the requirement of restraining arterial partial pressure of carbon dioxide (pCO(2)) from increasing (because of an increased ratio between increased physiologic dead space and tidal volume [VD/VT]) and the depression of arterial pCO(2) by further increased ventilation, which necessarily implies an important non-carbon dioxide stimulus to ventilation. We aimed to assess the contribution of these 2 factors in determining the elevated VE/VCO(2) slope in CHF. Thirty patients with CHF underwent cardiopulmonary exercise testing (age 65 +/- 11 years, left ventricular e…

Cardiomyopathy DilatedMalemedicine.medical_specialtyPartial PressureMyocardial IschemiaHyperpneaHypercapniaInternal medicineIdiopathic dilated cardiomyopathymedicineHumansTidal volumeAgedEjection fractionbusiness.industryVO2 maxRespiratory Dead SpaceCarbon DioxideMiddle Agedmedicine.diseasePulmonary AlveoliHeart failureExercise TestCardiologyBreathingFemaleAcidosis RespiratoryBlood Gas Analysismedicine.symptomPulmonary VentilationCardiology and Cardiovascular Medicinebusinesshuman activitiesHypercapniaThe American Journal of Cardiology
researchProduct

The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardio…

2013

Background: We assessed the influence of atorvastatin on selected indicators of an inflammatory condition, left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy (DCM). Methods. We included 68 DCM patients with left ventricular ejection fraction (LVEF) ≤40% treated optimally in a prospective, randomized study. They were observed for 5 years. Patients were divided into two groups: patients who were commenced on atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A), and patients who were treated according to current recommendations without statin therapy (group B). Results: After 5-year follow-u…

Cardiomyopathy DilatedMalemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinEndocrinology Diabetes and MetabolismClinical BiochemistryDiastoleCardiomyopathyDilated cardiomyopathyHemodynamicsHeart failureAtorvastatin Dilated cardiomyopathy Heart failure InflammationVentricular Function LeftEndocrinologyInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesAgedBiochemistry medicalInflammationEjection fractionbusiness.industryResearchBiochemistry (medical)Anti-Inflammatory Agents Non-SteroidalDilated cardiomyopathyMiddle Agedmedicine.diseaseUric AcidHospitalizationHeptanoic AcidsHeart failureCardiologyCytokinesFemalebusinessmedicine.drugFollow-Up StudiesLipids in health and disease
researchProduct

Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, str…

2003

Background: the effects of long-term administration of β-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. Patients and methods: patients with stable congestive heart failure (CHF) (New York heart association [NYHA] class II and III) and ejection fraction (EF) ≤0.40 were randomized to metoprolol, 50 mg t.i.d. or placebo for 6 months. Patients were divided into two groups: ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM). The mean EF was 0.29 in both groups and 92% were taking angiotensin-converting enzyme (ACE) inhibitors. In the IHD group, 84% had su…

Cardiomyopathy DilatedMalemedicine.medical_specialtyTime FactorsAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyRadionuclide angiographyDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathymedicineHumanscardiovascular diseasesMyocardial infarctionExerciseMetoprololEjection fractionVentricular Remodelingmedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyGated Blood-Pool ImagingHeartStroke VolumeAtrial fibrillationMiddle Agedmedicine.diseaseHeart failureExercise TestCardiologyFemaleCardiology and Cardiovascular MedicinebusinessMetoprololmedicine.drugEuropean Journal of Heart Failure
researchProduct

Sequential cardiovascular magnetic resonance assessment of left ventricular ejection fraction for prediction of subsequent events in a large multicen…

2021

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): This work was supported by “Instituto de Salud Carlos III” and “Fondos Europeos de Desarrollo Regional FEDER” Background. Cardiovascular magnetic resonance (CMR) is the best tool for left ventricular ejection fraction (LVEF) quantification, but as yet the prognostic value of sequential LVEF assessment for major adverse cardiac event (MACE) prediction after ST-segment elevation myocardial infarction (STEMI) is uncertain. Purpose. We explored the prognostic impact of sequential assessment of CMR-derived LVEF after STEMI to predict subsequent MACE. Methods. We recruited 1036 STEMI p…

Cardiovascular eventmedicine.medical_specialtyEjection fractionmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingGeneral MedicineCardiovascular deathInternal medicineCardiologyMedicineRadiology Nuclear Medicine and imagingCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Pressure–volume relationship by pharmacological stress cardiovascular magnetic resonance

2021

Abstract Background. The variation between rest and peak stress end-systolic pressure-volume relation (ΔESPVR) is an index of myocardial contractility, easily obtained during routine stress echocardiography and never tested during dipyridamole stress-cardiac magnetic resonance (CMR). We assessed the ΔESPVR index in patients with known/suspected coronary artery disease (CAD) who underwent dipyridamole stress-CMR.Methods. One-hundred consecutive patients (24 females, 63.76±10.17 years) were considered. ESPVR index was evaluated at rest and stress from raw measurement of systolic arterial pressure and end-systolic volume by biplane Simpson’s method. Results. The ΔESPVR index showed a good inte…

Cardiovascular magnetic resonance imagingReproducibilitymedicine.medical_specialtyCardiovascular magnetic resonance imaging; Dipyridamole; End-systolic pressure–volume relation; Myocardial contractilityEjection fractionmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingDipyridamolemedicine.diseaseDipyridamoleContractilityCoronary artery diseaseEnd-systolic pressure–volume relationInternal medicineCardiologyStress EchocardiographyMedicineRadiology Nuclear Medicine and imagingMyocardial contractilityCardiology and Cardiovascular MedicinebusinessCardiac imagingmedicine.drug
researchProduct

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction

2018

Aims The mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF) are not yet elucidated. Chronotropic incompetence has emerged as a potential mechanism. We aimed to evaluate whether heart rate (HR) response to exercise is associated to functional capacity in patients with symptomatic HFpEF. Methods and results We prospectively studied 74 HFpEF patients [35.1% New York Heart Association Class III, 53% female, age (mean ± standard deviation) 72.5 ± 9.1 years, and 59.5% atrial fibrillation]. Functional performance was assessed by peak oxygen consumption (peak VO2 ). The mean (standard deviation) peak VO2 was 10 ± 2.8 mL/min/kg. The following chronotropic pa…

Chronotropicmedicine.medical_specialtybusiness.industryAtrial fibrillationExercise intolerance030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicineHeart failureHeart ratemedicineCardiologyIn patient030212 general & internal medicinemedicine.symptomCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct